-DOCSTART- -X- O
OBJECTIVES -X- _ O
: -X- _ O
To -X- _ O
critically -X- _ O
appraise -X- _ O
the -X- _ O
efficacy -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
Kangfuxinye -X- _ B-Intervention
enema -X- _ I-Intervention
combined -X- _ I-Intervention
with -X- _ I-Intervention
mesalamine -X- _ I-Intervention
for -X- _ O
the -X- _ O
ulcerative -X- _ B-Patient
colitis -X- _ I-Patient
( -X- _ I-Patient
UC -X- _ I-Patient
) -X- _ I-Patient
patients -X- _ I-Patient
and -X- _ O
in -X- _ O
addition -X- _ O
to -X- _ O
grade -X- _ O
the -X- _ O
quality -X- _ O
of -X- _ O
evidence -X- _ O
by -X- _ O
using -X- _ O
the -X- _ O
GRADE -X- _ O
( -X- _ O
grading -X- _ O
of -X- _ O
recommendations -X- _ O
, -X- _ O
assessment -X- _ O
, -X- _ O
development -X- _ O
, -X- _ O
and -X- _ O
evaluation -X- _ O
) -X- _ O
approach. -X- _ O
METHODS -X- _ O
: -X- _ O
A -X- _ O
literature -X- _ O
search -X- _ O
was -X- _ O
performed -X- _ O
in -X- _ O
the -X- _ O
Cochrane -X- _ O
Library -X- _ O
, -X- _ O
MEDLINE -X- _ O
, -X- _ O
EMBASE -X- _ O
, -X- _ O
CBM -X- _ O
, -X- _ O
CNKI -X- _ O
, -X- _ O
VIP -X- _ O
, -X- _ O
and -X- _ O
WanFang -X- _ O
Databases. -X- _ O
The -X- _ O
search -X- _ O
restrictions -X- _ O
were -X- _ O
patients -X- _ O
with -X- _ O
UC -X- _ O
and -X- _ O
RCTs. -X- _ O
Studies -X- _ O
including -X- _ O
other -X- _ O
treatments -X- _ O
except -X- _ O
Kangfuxinye -X- _ O
with -X- _ O
mesalamine -X- _ O
were -X- _ O
excluded. -X- _ O
RESULTS -X- _ O
: -X- _ O
Nineteen -X- _ B-Outcome
studies -X- _ I-Outcome
met -X- _ I-Outcome
the -X- _ I-Outcome
inclusion -X- _ I-Outcome
criteria. -X- _ I-Outcome
We -X- _ I-Outcome
found -X- _ I-Outcome
significant -X- _ I-Outcome
benefits -X- _ I-Outcome
of -X- _ I-Outcome
Kangfuxinye -X- _ I-Outcome
combined -X- _ I-Outcome
with -X- _ I-Outcome
mesalamine -X- _ I-Outcome
against -X- _ I-Outcome
mesalamine -X- _ I-Outcome
alone -X- _ I-Outcome
in -X- _ I-Outcome
improving -X- _ I-Outcome
response -X- _ I-Outcome
rate -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
reducing -X- _ I-Outcome
the -X- _ I-Outcome
recurrence -X- _ I-Outcome
rate -X- _ I-Outcome
and -X- _ I-Outcome
inflammation -X- _ I-Outcome
rate -X- _ I-Outcome
; -X- _ I-Outcome
meanwhile -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
increase -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
rate -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
observed. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
symptoms -X- _ I-Outcome
remission -X- _ I-Outcome
rate -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
cure -X- _ I-Outcome
time -X- _ I-Outcome
were -X- _ I-Outcome
insignificant -X- _ I-Outcome
statistically. -X- _ I-Outcome
Additionally -X- _ I-Outcome
, -X- _ I-Outcome
GRADE -X- _ I-Outcome
results -X- _ I-Outcome
indicated -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
quality -X- _ I-Outcome
of -X- _ I-Outcome
evidence -X- _ I-Outcome
regarding -X- _ I-Outcome
the -X- _ I-Outcome
above -X- _ I-Outcome
6 -X- _ I-Outcome
outcomes -X- _ I-Outcome
was -X- _ I-Outcome
rated -X- _ I-Outcome
from -X- _ I-Outcome
very -X- _ I-Outcome
low -X- _ I-Outcome
to -X- _ I-Outcome
moderate -X- _ I-Outcome
quality. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Although -X- _ O
Kangfuxinye -X- _ B-Outcome
enema -X- _ I-Outcome
seems -X- _ I-Outcome
effective -X- _ I-Outcome
and -X- _ I-Outcome
safe -X- _ I-Outcome
for -X- _ I-Outcome
treating -X- _ I-Outcome
UC -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
systematic -X- _ I-Outcome
review -X- _ I-Outcome
, -X- _ I-Outcome
Kangfuxinye -X- _ I-Outcome
enema -X- _ I-Outcome
combined -X- _ I-Outcome
with -X- _ I-Outcome
mesalamine -X- _ I-Outcome
was -X- _ I-Outcome
weakly -X- _ I-Outcome
recommended -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
very -X- _ I-Outcome
low -X- _ I-Outcome
to -X- _ I-Outcome
moderate -X- _ I-Outcome
quality -X- _ I-Outcome
of -X- _ I-Outcome
available -X- _ I-Outcome
evidence -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
GRADE -X- _ I-Outcome
approach -X- _ I-Outcome
. -X- _ O

